Bing

The stock has a 50-day moving average price of $3.03 and a 200 ... Hoffmann-La Roche Ltd (Roche) and Genentech Inc., (Genentech), a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis’s development …
sleekmoney.com · 8/27/2015
The stock’s market capitalization is $304.28 million ... Hoffmann-La Roche Ltd (Roche) and Genentech Inc., (Genentech), a member of the Roche Group, under a collaboration agreement between Curis and Genentech.
Ticker Report · 8/26/2015
Exelixis, Inc. (NASDAQ:EXEL) is working with Genentech, a subsidiary of Roche Holding Ltd ... fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each …
INSIDER MONKEY · 8/27/2015
More from Bing News
Cobimetinib is a selective inhibitor of MEK that was discovered by Exelixis and is the subject of a worldwide collaboration agreement between Exelixis and Genentech ... an additional $2 billion of common stock
StreetInsider · 8/27/2015
ImmunoGen's stock has certainly been more kind to investors recently ... the company has already had success in bringing its first drug to market through a partnership with Genentech, which is a subsidiary of pharma …
The Motley Fool · 8/17/2015
ImmunoGen
Genentech Inc. stock will stop being traded at the end of today’s trading day — the end of an era for the Bay Area’s biotech giant — after Swiss drug giant Roche completed its $95-a-share tender offer for Genentech shares. Roche now holds 93.2 ...
The Business Journal · 3/26/2009
Dr Sean Bohen - joining on September 15 from Genentech, a Roche subsidiary - will be in charge ... lose more than 250 points at the open following the meltdown of the Chinese stock market. The spread betting firm IG …
Proactive Investors UK · 8/24/2015
FTSE
Punch Taverns sells 158 pubs to NewRiver Retail for £53.5 million. AstraZeneca poaches Genentech’s Sean Bohen as chief medical officer. Distribution and outsourcing group Bunzl's first half profits are up 6% to …
London Evening Standard · 8/24/2015
SAN FRANCISCO, May 3— The wife of Genentech's chief executive officer is the focus of an insider trading investigation being conducted by the Securities and Exchange Commission, the company disclosed today. The investigation concerns trading in ...
New York Times · ByAndrew Pollack · 5/4/1990
This article will complete the summary, put the pipeline in the context of the company and its stock market valuation ... and Roche (OTCQX:RHHBY), via its Genentech subsidiary's collaboration with a privately held company. The other major disclosed ...
Seeking Alpha · 8/24/2015
GILD